Both in Pharmaceuticals
AN2 Therapeutics vs Atrium Therapeutics
Over the past year ANTX returned +263.5% and RNA returned −87.5%; their daily moves had a correlation of -0.02.
ANTX +263.5% RNA −87.5%Growth of $1, one year, split-adjusted
| Metric | ANTX | RNA |
|---|---|---|
| Price | $4.18 | $8.72 |
| Market cap | $157.7M | $149.2M |
| Today | −3.91% | +1.99% |
| 1 month | −25.5% | +9.4% |
| 6 months | −10.9% | −32.5% |
| Year to date | +266.7% | −87.9% |
| 1 year | +239.8% | — |
| Revenue growth (YoY) | — | −21.9% |
| Gross margin | — | 100.0% |
| Net margin | — | −672.0% |
| P/E (TTM) | — | — |
| Price / sales | — | 4.1× |
| Net cash | $78.4M | $263.9M |
| Dividend yield | — | — |
| Volatility (60d) | 75.1% | 65.8% |
| Short % of float | 10.0% | 22.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).